Resources

Arrow® EZ-IO® System
Request Information
Australia and New Zealand / Product Areas / Emergency Medicine / Intraosseous Access / Arrow EZ-IO System / Cardiac Arrest

Intraosseous Access

Cardiac Arrest: One of the Leading Causes of Mortality1

There are greater than 500,000 adult occurrences of cardiac arrest yearly in the United States with an estimated 10% survival rate.1

Key to Treatment: Rapid Delivery of Fluids and Medication

Clinicians need the fastest method of establishing vascular access—and IV access may be difficult or impossible due to cardiovascular collapse and environmental challenges.


 

Success rates: IO > IV

Success rates for intraosseous vascular access have been shown to be superior to that of IV access during cardiac arrest in comparative clinical studies.2,3


 

Return of Spontaneous Circulation (ROSC): IO = IV

Rates of return of spontaneous circulation (ROSC) in cardiac arrest have been shown to be similar for patients that received IO and IV vascular access.2,3

Video Spotlight

Medical Director video image

A word from our Medical Director

A patient perspective video image

A patient perspective

Mock code video image

Mock code

The Proximal Humerus Advantage


 

  • Provides peripheral access with CVC performance4-7
  • Humeral IO access shown to facilitate rapid delivery of fluids and medications in cardiac arrest and peri-arrest situations8,9
  • 97% first-attempt access success rate10
  • Less than 1% serious complication rate11
  • Just three seconds to reach the heart with medication or fluid4,12
  • Lower insertion and infusion pain as compared to EZ-IO System tibial insertions13

Learn More

Download the EZ-IO System App

Apple App Store Google Play Store
While the articles support intraosseous vascular access indications, claims and applications of Arrow EZ-IO Intraosseous Vascular Access System, readers should consult a physician and product labeling for proper indications, contraindications, warnings and precautions prior to use.

Potential complications may include local or systemic infection, hematoma, extravasations, or other complications associated with percutaneous insertion of sterile devices.

Rx only

References:

  1. Mozaffarian D, Benjamin EJ, Go AS, et al: on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. DOI: 10.1161/CIR.0000000000000152.
  2. Clemency B, Tanaka K, May P, et al. Intravenous vs. intraosseous access and return of spontaneous circulation during out of hospital cardiac arrest. Am J Emerg Med. Oct 2016. doi: 10.1016/j.ajem.2016.10.052.
  3. Bramlett E, Fales W, West B, LaBond V. Rate of return of spontaneous circulation in relation to primary vascular access during out-of-hospital adult cardiac arrest. Ann Emerg Med. 2016;68(4S):S120.
  4. Based on Adult Proximal Humerus EZ-IO insertion data.
  5. Compared to single lumen CVCs.
  6. Hoskins SL, Zachariah BS, Copper N, Kramer GC. Comparison of intraosseous proximal humerus and sternal routes for drug delivery during CPR. Circulation 2007; 116:II_993. Research sponsored by Teleflex Incorporated. (preclinical study)
  7. Hoskins SL, Nascimento P Jr., Lima RM, Espana-Tenorio, JM, Kramer GC. Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. Resuscitation 2011; doi:10.1016/j.resuscitation.2011.07.041. Research sponsored by Teleflex Incorporated. (preclinical study)
  8. Ross EM, Mapp J, Kharod CU. Time to epinephrine in out-of-hospital cardiac arrest: a retrospective analysis of intraosseous versus intravenous access. Ann Emerg Med. 2016;68(4s):S61.
  9. Lewis P, Wright C. Saving the critically injured trauma patient: a retrospective analysis of 1,000 uses of intraosseous access. Emerg Med J. 2014;31(9):784. doi:10.1136/emermed-2014-203588.
  10. Cooper BR, Mahoney PF, Hodgetts TJ, Mellor A. Intra-osseous access (EZ-IO) for resuscitation: UK military combat experience. J R Army Med Corps. 2007;153(4):314-316.
  11. Teleflex Internal Data on File 2014.
  12. Montez D, Puga T, Miller LJ, et al. Intraosseous infusions from the proximal humerus reach the heart in less than 3 seconds in human volunteers. Annals of Emergency Medicine. 2015;66(4S):S47. Research sponsored by Teleflex Incorporated.
  13. Philbeck TE, Miller LJ, Montez D, Puga T. Hurts so good; easing IO pain and pressure. JEMS. 2010;35(9):58-69. Research sponsored by Teleflex Incorporated.
Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries.
Google Play is a trademark of Google Inc.
Teleflex, the Teleflex logo, Arrow, EZ-Connect, EZ-IO and EZ-Stabilizer are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. MCI-2020-0755